Immunomedics, Inc., (Nasdaq: IMMU) today announced that sacituzumab govitecan, the Company's lead investigational antibody-drug conjugate (ADC), continues to produce durable ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE